Jonathan M. Eby

Jonathan M. Eby

Auto-generated profile, based on publicly available information

Jonathan M. Eby

Becton, Dickinson and Company, Vernon Hills, IL

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2013 in Science Translational Medicine
Verified
Journal Article
Closed access
JMJeffrey A. Mosenson
Jeffrey A. Mosenson
Andrew ZlozaAndrew Zloza
Andrew Zloza
John Dirk Vestergaard  NielandJohn Dirk Vestergaard Nieland
John Dirk Vestergaard Nieland
EGElizabeth Garrett-Mayer
Elizabeth Garrett-Mayer
JEJonathan M. Eby
Jonathan M. Eby
IPI. Caroline Le Poole
I. Caroline Le Poole
Vitiligo can be reversed through immune targeting with mutant heat shock protein 70.

1 May 2014 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
PDF file
SCShilpak Chatterjee
Shilpak Chatterjee
JEJonathan M. Eby
Jonathan M. Eby
AAAmir A. Al-Khami
Amir A. Al-Khami
MSMyroslawa Soloshchenko
Myroslawa Soloshchenko
HKHee-Kap Kang
Hee-Kap Kang
Shikhar MehrotraShikhar Mehrotra
Shikhar Mehrotra
T-cell cytolytic activity targeting epidermal melanocytes is shown to cause progressive depigmentation and autoimmune vitiligo. By using the recently developed transgenic mice h3TA2 that carry T cells with a HLA-A2-restricted human tyrosinase peptide (h-Tyr)–reactive TCR and develop spontaneous vitiligo from an early age, we addressed the mechanism regulating autoimmune vitiligo. Depigmentation was significantly impaired only in IFN-γ-knockout h3TA2 mice but not in TNF-α- or perforin-knockout h3TA2 mouse strains, confirming a central role for IFN-γ in vitiligo development. In addition, regulatory T cells (Tregs) were relatively abundant in h3TA2-IFN-γ-/- mice, and depletion of the Treg–engaging anti-CD25 antibody fully restored the depigmentation phenotype in h3TA2-IFN-γ-/- mice, mediated in part through the upregulation of proinflammatory cytokines such as IL-17 and IL-22. Further therapeutic potential of Treg abundance in preventing progressive depigmentation was evaluated by adoptively transferring purified Treg or using rapamycin. Both the adoptive transfer of Tregs and the use of rapamycin induced a lasting remission of vitiligo in mice treated at the onset of disease, or in mice with established disease. This leads us to conclude that reduced regulatory responses are pivotal to the development of vitiligo in disease-prone mice, and that a quantitative increase in the Treg population may be therapeutic for vitiligo patients with active disease.

6 July 2015 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
KWK.C. Webb
K.C. Webb
RTR. Tung
R. Tung
LWL.S. Winterfield
L.S. Winterfield
AGA.B. Gottlieb
A.B. Gottlieb
JEJ.M. Eby
J.M. Eby
IPI.C. Le Poole
I.C. Le Poole
Tumour necrosis factor (TNF)‐α, a proinflammatory cytokine central to many autoimmune diseases, has been implicated in the depigmentation process in vitiligo. We review its role in vitiligo by exploring its pro‐ and anti‐inflammatory properties and examine the effects of blocking its actions with TNF‐α antagonist therapeutics in reports available in the literature. We found that TNF‐α inhibition halts disease progression in patients with progressive vitiligo but that, paradoxically, treatment can be associated with de novo vitiligo development in some patients when used for other autoimmune conditions, particularly when using adalimumab and infliximab. These studies reinforce the importance of stating appropriate outcomes measures, as most pilot trials propose to measure repigmentation, whereas halting depigmentation is commonly overlooked as a measure of success. We conclude that TNF‐α inhibition has proven useful for patients with progressive vitiligo, where TNF‐α inhibition is able to quash cytotoxic T‐cell‐mediated melanocyte destruction. However, a lingering concern for initiating de novo disease will likely prevent more widespread application of TNF inhibitors to treat vitiligo.

20 December 2013 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
PDF file
JMJeffrey A. Mosenson
Jeffrey A. Mosenson
KFKelsey Flood
Kelsey Flood
JKJared Klarquist
Jared Klarquist
JEJonathan M. Eby
Jonathan M. Eby
AKAmy Koshoffer
Amy Koshoffer
IPI. Caroline Le Poole
I. Caroline Le Poole

1 June 2015 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PDF file
JEJonathan M. Eby
Jonathan M. Eby
HKHee-Kap Kang
Hee-Kap Kang
STSean T. Tully
Sean T. Tully
WBWendy E. Bindeman
Wendy E. Bindeman
DPDaniel S. Peiffer
Daniel S. Peiffer
IPI. Caroline Le Poole
I. Caroline Le Poole

29 May 2013 in Experimental Dermatology
Verified
Journal Article
Open access
PDF file
JMJeffrey A. Mosenson
Jeffrey A. Mosenson
JEJonathan M. Eby
Jonathan M. Eby
CHClaudia Hernandez
Claudia Hernandez
IPI. Caroline Le Poole
I. Caroline Le Poole
Inducible heat‐shock protein 70 (HSP70i) is a protein regulated by stress that protects cells from undergoing apoptosis. Such proteins are marvellously well conserved throughout evolution, which has placed them in the spotlight for helping to understand the intriguing relationship between infection and immunity. In the presence of stress proteins, dendritic cells (DCs) will sense this alarm signal and respond by recruiting immune cells of different plumage to fit the occasion. In times of stress, melanocytes will secrete antigen‐bound HSP70i to act as an alarm signal in activating DCs that comes equipped with an address of origin to drive the autoimmune response in vitiligo. Here we pose that if the autoimmune response is funnelled through HSP70i, then blocking the stress protein from activating DCs can lend new treatment opportunities for vitiligo.